معرفی
Professor Julien Reboud is a prominent researcher in Biomedical Engineering at the University of Glasgow, specializing in the integration of engineering and biology for healthcare applications. With extensive experience from his PhD in France and postdoctoral work in Singapore, he has established a strong track record in microfluidic systems development for cell-based assays, diagnostics, and drug discovery. His work bridges the gap between academic research and commercial applications, having co-founded companies like SAW Dx Ltd and NebuFlow Ltd.
Reboud's research focuses on three main areas: acoustofluidics for sample manipulation with diagnostic applications, synthetic biology using microfluidics for artificial cell platforms, and low-cost/zero-cost diagnostics for resource-limited settings. His work emphasizes developing technologies suitable for low-resource environments, particularly in the developing world, where acoustic platforms offer low-cost, low-power solutions for complex bioassays without requiring large infrastructure. His expertise spans microfluidics, surface acoustic waves, phononics, microfabrication, cell-based assays, and synthetic biology.
His recent publications demonstrate a strong emphasis on point-of-care diagnostic technologies, particularly for infectious diseases and veterinary applications. There's a clear trend toward developing integrated solutions that combine microfluidics with smartphone technology, blockchain, and AI for decision support in field settings. His work increasingly addresses global health challenges, with multiple publications focused on diagnostics for use in developing countries and resource-limited environments.
- The Royal Academy of Engineering ERA Foundation Entrepreneurs prize
- PhD prize in the French national start-up competition (2004)
- Highly Commended Technology and Innovation at the Times Higher Education Awards (2014)
Professor Reboud has successfully translated his research into commercial applications through spin-out companies SAW Dx Ltd and NebuFlow Ltd. His work demonstrates strong industry collaboration, particularly in integrating microfluidic systems for diagnostics and drug discovery. His research group actively collaborates with healthcare professionals and researchers in Africa to develop and deploy diagnostic innovations in low-resource settings. With over 70 peer-reviewed publications and 15 patent applications (2 granted), his work has significant impact in both academic and commercial spheres.
His research group develops advanced techniques for designing and fabricating acoustic systems, novel assay designs, and paper-based microfluidic solutions. The team works extensively on creating open innovations in diagnostics that can be deployed in resource-limited settings, covering both materials/processes for assays and digital technologies for field decision support.
